Bouncebackability portends increased risk of adverse outcomes in RA
Dr. Richard Conway discusses Abstract 2218 at ACR22 Convergence.
Abstract 2218: Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia.
Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Efficacy and Safety Results from BE OPTIMAL in PsA
Dr. Arthur Kavanaugh discusses abstract L02 ACR22 Convergence in Philadelphia, PA.
L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Hydroxychloroquine Update from ACR22
Dr. Michelle Petri reviews several abstracts presented at ACR22 Convergence.
Abstracts 0343, 0538, 0976, 0983, 0981, 0980
RA: Steroids are bad, again
Dr. Richard Conway discusses Abstract 2219 at ACR22 Convergence
Abstract 2219: Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Tofacitinib and RA-ILD
Dr. Richard Conway discusses Abstract 2251 at ACR22 Convergence.
Abstract 2251: Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
Life or Organ Threatening SLE: What To Do? Is There Anything New?
Dr. Michelle Petri discusses Abstracts 1651, 1677 at ACR22 Convergence in Philiadelphia, PA.
EULAR 2024 Daily Podcasts Day1&2
Predicting Palindromic Prognosis
A Step Closer to Identifying Phenotypes of RA ILD
Top 3 Messages About JAK Inhibitor Safety
Pain in RA: Different Drugs for Different Mechanisms
Giant Cell Arteritis and Polymyalgia Rheumatica Update
JAK Inhibitors for New Indications
Top 3 Messages About JAK Inhibitor Safety
Pain in RA: Different Drugs for Different Mechanisms
JAK Inhibitors for New Indications
Potential of Radiomics to Predict TNF Therapy Outcomes in axSpA
Treat to Target Outcomes in Early AxSpA
Does Telemonitoring in SpA Work?
PsA Treatment: is Earlier Better?
JAK Inhibitors for New Indications
Transition from Psoriasis to PsA: Can we Prevent It?
EULAR 2024 Daily Recap - Days 1 & 2
Mechanistic Promise in RA Doesn’t Always Mean Actual Gain
The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive